Glenn has over 20 years experience in clinical development. Before joining Recursion, Glenn was leading clinical development at both small and large bio-pharma companies. He spent six years at Genentech and Roche, where he led the Phase 3 implementation of global clinical development for two anti-amyloid antibodies in Alzheimer's disease. Subsequently, he was VP of Global Clinical Development at Zogenix, where he led global clinical development to deliver U.S. and European Medicines Agency approvals of fenfluramine for Dravet syndrome. Most recently, he was VP of Neurology Clinical Development at Alector, where he led the design and execution of development programs in neurology, with a specific focus on Alzheimer's disease and ALS. Glenn earned his BSc, and MSc and PhD in neurobiology all from the University of Toronto, and did a post-doc at UCLA. Glenn is an an avid golfer, and enjoys sports cars and car detailing.